Market Performance Overview
Iradimed Corp. (ticker IRMD) concluded the 24‑hour trading window on Saturday, 24 September 2026, with a decline of 2.08 %. At 06:23 AM Central European Time, the shares traded at approximately USD 85.82. The company’s current share supply stands at 12.8 million, supporting a market capitalization of USD 1.1 billion. During the same period, roughly USD 9.2 million of Iradimed stock changed hands on public exchanges.
Despite the recent dip, Iradimed’s performance over the longer term has been modestly positive; from the end of the previous month to the present, the share price has risen by 0.73 %. The 200‑day simple moving average, a key technical indicator for trend analysis, sits at USD 92.96, suggesting that the stock remains below its medium‑term average. In the 52‑week range, Iradimed reached a peak of USD 107.90 on 2 October 2026 and a trough of USD 75.75 on 30 October 2025, illustrating a relatively narrow annual range of volatility.
Peer Performance Snapshot
The performance of comparable equities during the last 24 hours provides context for Iradimed’s recent movement:
| Symbol | 24‑hour change | Current price (USD) | Market cap (USD) | P/E ratio |
|---|---|---|---|---|
| FOR | –0.5 % | 26.09 | 1.3 billion | 7.84 |
| COUR | +0.2 % | 5.08 | 1.3 billion | – |
| CRCT | –2.5 % | 6.25 | 1.3 billion | 15.99 |
| NSSC | +0.57 % | 38.82 | 1.3 billion | 31.84 |
| DMRA | –2.86 % | 21.09 | 1.3 billion | – |
These figures indicate a mixed performance across the sector, with the majority of peer companies experiencing slight declines or modest gains, while a few, such as Napco Security, posted a small positive move.
Company Profile
Iradimed Corp. is headquartered in Winter Springs, Florida, and operates within the health‑care equipment and supplies sector. The company specializes in the design, manufacture, and distribution of non‑magnetic intravenous infusion pump systems, which are integral to patient care during magnetic resonance imaging (MRI) procedures. By providing equipment that safely interfaces with MRI environments, Iradimed addresses a critical need for precision and safety in modern diagnostic imaging.
Concluding Remarks
The recent 2.08 % drop in Iradimed’s share price reflects broader market dynamics rather than a fundamental shift in the company’s strategic position. With a solid market capitalization and a product line that serves a niche but essential market segment, the company remains positioned to capitalize on continued demand for MRI‑compatible infusion technology. Investors monitoring Iradimed should consider the broader sector performance, technical indicators, and the company’s long‑term value proposition when assessing its future trajectory.
